<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218425</url>
  </required_header>
  <id_info>
    <org_study_id>10-3-056</org_study_id>
    <nct_id>NCT01218425</nct_id>
  </id_info>
  <brief_title>Dopaminergic Modulation of Cognition and Psychomotor Function</brief_title>
  <official_title>Dopaminergic Modulation of Cognition and Psychomotor Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A recent study at our lab showed increased episodic memory consolidation and response
      readiness after treatment with methylphenidate in healthy volunteers. The investigators seek
      to replicate and extend these findings. Furthermore the pharmacological specificity of these
      effects will be studied. Since methylphenidate has an effect on two neurotransmitters,
      dopamine and noradrenaline, either could be responsible for the observed effects. In order to
      explore the dopaminergic contribution to this effect, the study proposed here includes not
      only methylphenidate but also levodopa/carbidopa, which only affects dopamine and not
      noradrenaline.

      In this study, 20 healthy males and females between 18 and 45 years of age will participate.
      They will be recruited via advertisements at Maastricht University and in local newspapers.

      Participants will be treated once with methylphenidate, once with levodopa/carbidopa and once
      with placebo. All medications will be administered orally with a capsule.

      It is hypothesized that methylphenidate and levodopa/carbidopa will both enhance episodic
      memory consolidation and improve response readiness
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioral score on the Word learning test</measure>
    <time_frame>1 day</time_frame>
    <description>Number of words recalled in the word learning test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CNV amplitude</measure>
    <time_frame>1 day</time_frame>
    <description>Amplitude of the CNV wave in the EEG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reaction time on the CNV</measure>
    <time_frame>1 day</time_frame>
    <description>Reaction time in the response preparation task in which CNV is measured</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dopamine Activity</condition>
  <condition>Episodic Memory Consolidation</condition>
  <condition>Response Preparation</condition>
  <arm_group>
    <arm_group_label>Medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, a crossover design is applied. All participants receive all three treatments in randomized order on separate days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate 40 mg</intervention_name>
    <description>Oral dose 40 mg</description>
    <arm_group_label>Medication</arm_group_label>
    <other_name>Ritalin RVG 03957</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/carbidopa 125 mg</intervention_name>
    <description>oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule</description>
    <arm_group_label>Medication</arm_group_label>
    <other_name>Sinemet RVG08740</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidon 10 mg</intervention_name>
    <description>Domperidon 10 mg</description>
    <arm_group_label>Medication</arm_group_label>
    <other_name>Domperidon RVG 23565</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  18 to 45 years of age

          -  Healthy (i.e. absence of all exclusion criteria), normal static binocular acuity
             (corrected or uncorrected),

          -  Body mass index between 18.5 and 30

          -  Willingness to sign an informed consent.

        Exclusion Criteria:

          -  history of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal,
             haematological or psychiatric illness.

          -  history of depression, bipolar disorder, anxiety disorder, panic disorder, psychosis,
             or attention deficit hyperactivity disorder will be excluded from participation.

          -  first-degree relative with a psychiatric disorder or a history with a psychiatric
             disorder

          -  excessive drinking (&gt;20 glasses of alcohol containing beverages a week

          -  pregnancy or lactation

          -  use of medication other than oral contraceptives

          -  use of recreational drugs from 2 weeks before until the end of the experiment

          -  any condition in which gastrointestinal motility might carry any risk

          -  any sensory or motor deficits which could reasonably be expected to affect test
             performance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Vuurman, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Neuropsychology and Psychopharmacology, Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <last_update_submitted>October 24, 2012</last_update_submitted>
  <last_update_submitted_qc>October 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dopamine</keyword>
  <keyword>EEG</keyword>
  <keyword>episodic memory</keyword>
  <keyword>contingent negative variation</keyword>
  <keyword>response preparation</keyword>
  <keyword>levodopa</keyword>
  <keyword>methylphenidate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Domperidone</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

